Steven Jeffrey Hager DO

Oncology•Fresno, CA

Physician

Join to View Full Profile

7130 N Millbrook AveFresno, CA 93720
Phone+1 559-326-1222
Fax+1 559-326-1230

Education & Training

Naval Medical Center (San Diego)Fellowship, Hematology and Medical Oncology, 1993 - 1996
National Capital ConsortiumResidency, Internal Medicine, 1988 - 1991
NYIT College Of Osteopathic MedicineClass of 1984

Certifications & Licensure

CA State License 2002 - 2025
VA State License 1999 - 2016
FL State License 1991 - 2004
NC State License 2001 - 2004
MI State License 1984 - 1985
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012

Clinical Trials

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients Start of enrollment: 2011 Apr 01
Completed
Phase 1
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer Start of enrollment: 2013 Mar 25
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Observational Registry Study of Quality of Life When Treating BTcP With Abstral Start of enrollment: 2013 Oct 01
Completed
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Phase 2
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Start of enrollment: 2020 Jul 23
COMPLETED
PHASE3
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
COMPLETED
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

5 citations
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang
Blood Advances. 2024-03-26
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer HarboringL747P Mutation With Clinical Response to Multi-targeted Epigenetic andInh...
Samia S Messeha, Mohammad A Nezami, Steven Hager, Karam F A Soliman
Anticancer Research. 2022-01-01
9 citations
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.
Jeffrey L. Vacirca, Arlene Chan, Klára Mezei, Clarence S. Adoo, Zsuzsanna Pápai
Cancer Medicine. 2018-05-01

Press Mentions

4/20, the Marijuana Holiday, ExplainedApril 20th, 2021

Professional Memberships

American Osteopathic Association - AOA
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member